Royal Bank Of Canada Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective upped by equities research analysts at Royal Bank Of Canada from $696.00 to $737.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential downside of 3.54% from the company’s previous close.

Other research analysts also recently issued research reports about the company. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday. Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research note on Friday. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $794.83.

Regeneron Pharmaceuticals Stock Up 3.5%

Shares of REGN traded up $25.68 during mid-day trading on Friday, reaching $764.02. 741,618 shares of the stock traded hands, compared to its average volume of 858,210. The firm has a market cap of $80.77 billion, a price-to-earnings ratio of 18.62, a P/E/G ratio of 27.78 and a beta of 0.24. The stock has a fifty day simple moving average of $640.66 and a 200 day simple moving average of $711.35. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.81 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals will post 2.06 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in REGN. Lockheed Martin Investment Management Co. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $2,702,000. Orbimed Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $11,358,000. Asio Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $3,422,000. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after purchasing an additional 140,966 shares during the last quarter. Finally, National Pension Service lifted its holdings in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after purchasing an additional 82,853 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and ahead of the $3.82 billion consensus estimate. Non-GAAP EPS was $14.29, substantially above the $10.16 analyst forecast. Growth was led by record Dupixent sales, which rose 38%, and EYLEA HD U.S. sales, which increased 52%. Regeneron Second-Quarter Results
• Positive Sentiment: Analysts raised their price targets following the results. Cantor Fitzgerald increased its target to $795 and retained an overweight rating, while Truist lifted its target to $772 and maintained a buy rating. These revisions suggest continued confidence in the company’s commercial portfolio and pipeline. Analyst Price-Target Updates
• Positive Sentiment: The earnings call highlighted record demand for Dupixent and EYLEA HD, as well as a collaboration with Telix Pharmaceuticals to develop radiopharmaceutical cancer therapies. The deal could broaden Regeneron’s oncology pipeline over time. Q2 Earnings Call Transcript
• Neutral Sentiment: Morgan Stanley and Wells Fargo also raised their price targets, to $758 and $750, respectively, but kept equal-weight ratings. Their targets indicate limited upside at recent trading levels and reflect a more cautious view of valuation.
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The dividend provides modest income support, with an indicated yield of roughly 0.5%.
• Negative Sentiment: Several law firms announced or promoted securities class-action activity related to disclosures surrounding the failed Phase 3 Fianlimab-Libtayo melanoma trial. The alleged misrepresentations concern the trial’s protocol and slowing event accrual; the prior failure reportedly erased about $11 billion in market value. While the notices largely repeat existing litigation, they add legal and reputational risk for REGN. Regeneron Securities Class Action

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.